Michael Pulley is a Neurology physician affiliated with University of Florida. OpenAlex indexes 63 publications with 4,393 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
580 W 8th St
Ufjp Neurology
Jacksonville, FL 322096533
Telephone
904-244-3960Registry record last updated 12 Jun 2009.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20259 payments
- Otsuka Pharmaceutical Development & Commercialization, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
44.1%Gabapentinoids7.6%Gabapentin73%Pregabalin28%Part D<11 patientsOther nervous system drugs6.9%Radicava Ors100%Part D≥18 patients+ 8 more classes in this area
Metabolism & gastrointestinal
35.4%Corticosteroid32.1%Prednisone100%Part D≥72 patientsAntidiarrheal microorganisms2.2%Folic Acid100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
9.5%Folate Analog Metabolic Inhibitor6.1%Methotrexate100%Part D≥18 patientsComplement Inhibitor2.2%Ultomiris100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumab
Journal of the Neurological Sciences
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Haller, MD
University of Florida
Peter Draganov, MD
University of Florida
Irene Malaty, MD
University of Florida
Laura Jacobsen, MD
University of Florida
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”